Apellis Pharmaceuticals Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Apellis Pharmaceuticals Inc 's ROA in the first quarter of 2026?
Apellis Pharmaceuticals Inc achieved a return on average assets (ROA) of 13.31 % in its first quarter of 2026, this is above APLS's average return on assets of -53.85%.
Apellis Pharmaceuticals Inc assets over the 12 months ending in its first quarter of 2026 are valued at $1,002 million

ROA has improved compared to 2.41% in the fourth quarter of 2025, due to net income growth.

However, within the Healthcare sector 74 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 438, from total ROA ranking in the fourth quarter of 2025 at 2032.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	36.47 %	23.46 %	17.55 %	-9.22 %	-2.98 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	133	22	45	-228	-224
Return On Assets (TTM)	13.31 %	2.41 %	5.12 %	-27.19 %	-26.02 %
APLS's Total Ranking	# 438	# 2032	# 1180	# 3719	# 3757
Total Assets (TTM) in million	1,083	1,075	1,041	808	793
Seq. Total Assets Change	0.68 %	3.33 %	28.83 %	1.83 %	-8.92 %
Seq. Net Income Change	-	-	-	-	-

APLS's 5 Years Annual ROA >> Back to APLS Management Effectiveness >> Compare APLS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 31
Sector	# 75
Overall	# 432

Return On Assets Statistics
High	Average	Low
13.2 %	-53.85 %	-102.33 %
(Mar 31 2026)		(Dec 31 2021)

News about Apellis Pharmaceuticals Inc Return on Assets ROA

Apellis Pharmaceuticals' Strategic Equity Inducement Awards Ignite Growth PotentialExplanation: This title emphasizes the proactive and calculated approach of Apellis Pharmaceuticals in bolstering its workforce and setting the stage for enhanced growth opportunities. It signifies the positive trajectory the company is embarking upon by aligning employee interests with long-term success.

Apellis Pharmaceuticals, a leading global biopharmaceutical company specializing in complement, recently announced the approval of equity awards for several new employees. These equity awards, granted under Nasdaq Listing Rule 5635(c)(4) and falling under the terms of the 2020 Inducement Stock Incentive Plan, serve as an indispensable factor in attracting and securing top talents.
Impact on the Company:
Apellis Pharmaceuticals has recorded a cumulative net loss of $-606 million during the 12 months ending in the third quarter of 2023, reflecting a negative return on assets (ROA) of -71.1%. However, inspite of these financial challenges, the company has taken a bold step in strengthening its workforce through the provision of equity inducement awards. This strategic move holds the promise of influencing the future success and growth of the company.

Apellis Pharmaceuticals Faces Obstacles as CHMP Gives Negative Opinion on Pegcetacoplan for GA Treatment in EU; Planned Re-Examination to Determine Future

By
Date: Today s Date
WALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a blow to its plans for the marketing authorization of intravitreal pegcetacoplan in the European Union (EU) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a negative opinion on the company s application, putting a halt to Apellis Pharmaceuticals progress in the EU market.
This news does not come as a surprise, as a negative trend vote was anticipated after an oral explanation meeting held in December 2023. However, Apellis Pharmaceuticals remains determined to move forward and has announced its plans to seek immediate re-examination of its application.

Financial Statements
Apellis Pharmaceuticals Inc 's Assets	$ 1,083 million	APLS's Balance sheet
Apellis Pharmaceuticals Inc 's Income	$ 19 million	Quarterly APLS's Income Statement
APLS's Income by Division		See APLS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	23.46 %	12.71 %	4.04 %	-13.87 %	-8.66 %
Total Assets in million	1,075	871	773	743	862
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	22	-198	-529	-652	-746
Annual Return On Assets	2.08 %	-22.72 %	-68.42 %	-87.81 %	-86.56 %

APLS's 5 Years Annual ROA >> Back to APLS Management Effectiveness >> Compare APLS ROA to its Competitors

Comment on APLS's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 2.08 % compared to prior year, due to annual net income growth of % to $22.39 million, while value of Apellis Pharmaceuticals Inc 's overall assets grew just by 23.46 % to $1,075.26 million, compared to $1,075.26 a year before.

More Return On Assets Ratios
APLS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
APLS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for APLS's Competitors
Subscribers only: Roa for Apellis Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for APLS's Customers

You may also want to know
APLS's Roi	APLS's Inventory Turnover Ratio	APLS's Growth Rates	APLS's Dividend Comparisons
	APLS's Profitability Ratios	APLS's Asset Turnover Ratio	APLS's Dividend Growth
APLS's Roe	APLS's Valuation Ratios	APLS's Financial Strength Ratios	APLS's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector	ROA
Omeros Corporation	34.53 %
Idexx Laboratories Inc	32.56 %
Innoviva Inc	32.36 %
Agenus Inc	30.03 %
Abeona Therapeutics Inc	29.55 %
Escalon Medical Corp	29.20 %
Protagenic Therapeutics Inc new	27.96 %
Adma Biologics Inc	27.37 %
Rafael Holdings Inc	26.85 %
Acadia Pharmaceuticals Inc	26.24 %
Ironwood Pharmaceuticals inc	26.02 %
Theravance Biopharma inc	25.46 %
Spero Therapeutics Inc	24.95 %
Medpace Holdings Inc	24.79 %
Mettler toledo International Inc	24.47 %
Qhslab Inc	23.09 %
Eli Lilly And Company	22.73 %
Incyte Corporation	21.65 %
Iradimed Corporation	21.25 %
Catalyst Pharmaceuticals Inc	20.71 %
Engene Therapeutics Inc	20.52 %
Vaxart Inc	20.07 %
Indivior Pharmaceuticals Inc	19.14 %
Pro dex Inc	18.35 %
Electromed Inc	18.31 %
Soleno Therapeutics Inc	18.25 %
Resmed Inc	18.18 %
Protalix Biotherapeutics inc	17.75 %
Krystal Biotech Inc	17.62 %
Zoetis Inc	17.54 %

Date modified: 2026-08-30T14:57:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.